One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson's disease – AbbVie – is ducking out of the challenge.
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study.
Swiss digital health company MindMaze has raised $105 million to help take its digital therapeutics (DTx) for neurological diseases like stroke onto the global stage, and fund the developme
Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that
GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the discovery of new medicine
Novartis has licensed a potential drug for Parkinson's from Belgium's UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlie
Great advances in cancer care have led to a new phase of research in certain cancers – in areas where a high rate of cure has been established, the focus is shifting to quality of life, sid